X4 Pharmaceuticals, Inc. (XFOR)
Automate Your Wheel Strategy on XFOR
With Tiblio's Option Bot, you can configure your own wheel strategy including XFOR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XFOR
- Rev/Share 4.5854
- Book/Share 3.3544
- PB 1.0494
- Debt/Equity 0.1051
- CurrentRatio 3.6971
- ROIC -0.0804
- MktCap 20376365.0
- FreeCF/Share -16.5115
- PFCF -0.1804
- PE 1.6493
- Debt/Assets 0.0186
- DivYield 0
- ROE 0.2932
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript
Read More
X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026
Read More
X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript
Published: March 25, 2025 by: Seeking Alpha
Sentiment: Neutral
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Daniel Ferry - IR, LifeSci Advisors Paula Ragan - CEO Adam Mostafa - CFO Christophe Arbet-Engels - Chief Medical Officer Mark Baldry - CCO Conference Call Participants Stephen Willey - Stifel Ed Tenthoff - Piper Sandler Ayan Hussein - Cantor Fitzgerald Doug MacPherson - H.C. Wainwright David Bautz - Zacks Small-Cap Research Operator Greetings, and welcome to the X4 Pharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
Read More
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or 4Q 2025; top-line data anticipated in 2H 2026
Read More
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries
Published: February 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt Agreement covers Saudi Arabia, United Arab Emirates, Qatar, Oman, Kuwait, Bahrain, and Egypt
Read More
About X4 Pharmaceuticals, Inc. (XFOR)
- IPO Date 2017-11-16
- Website https://www.x4pharma.com
- Industry Biotechnology
- CEO Dr. Paula Ragan Ph.D.
- Employees 143